FDA warning montelukast 03.2020—Statement of the Austrian working group of pediatric pulmonology and allergology
| العنوان: | FDA warning montelukast 03.2020—Statement of the Austrian working group of pediatric pulmonology and allergology |
|---|---|
| المؤلفون: | Anna Zschocke, Fritz Horak, Ernst Eber, Thomas Frischer, Burkhardt Simma, Wolfgang Stetzl, Josef Riedler, Zsolt Szépfalusi, Angela Zacharasiewicz |
| المصدر: | Wiener klinische Wochenschrift. 134:86-88 |
| بيانات النشر: | Springer Science and Business Media LLC, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Cyclopropanes, Austria, Pulmonary Medicine, Quinolines, Humans, Infant, Anti-Asthmatic Agents, General Medicine, Acetates, Sulfides, Child |
| الوصف: | Montelukast, a leukotriene receptor antagonist (LTRA) has been approved for use in Europe since 1998. Indications for use (from the age of 6 months) include mild to moderate asthma, seasonal allergic rhinitis with asthma, and the prevention of exercise-induced asthma episodes. The psychiatric side effects of montelukast have been known for the last 10 years; in the case of such symptoms benefits and risks should be considered. Due to potential life-threatening psychiatric adverse events, particularly suicide, a black box warning was issued. In this statement the Austrian working group of pediatric pulmonology and allergology advises that treatment with montelukast should be started only after critical evaluation. Treatment should be stopped on the occurrence of any neuropsychiatric side effects. |
| تدمد: | 1613-7671 0043-5325 |
| DOI: | 10.1007/s00508-021-01981-1 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c5008394de84be178efa63df87115b80 https://doi.org/10.1007/s00508-021-01981-1 |
| Rights: | CLOSED |
| رقم الانضمام: | edsair.doi.dedup.....c5008394de84be178efa63df87115b80 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 16137671 00435325 |
|---|---|
| DOI: | 10.1007/s00508-021-01981-1 |